Transcript Pharming title slide

Pharming Overview
May 2006
This presentation contains forward looking statements that involve known and unknown
risks, uncertainties and other factors, which may cause the actual results, performance or
achievements of the Company to be materially different from the results, performance or
achievements expressed or implied by these forward looking statements.
Powered
Powered by
by Bioscience,
Bioscience, Focused
Focused on
on Products
Products
1
Overview
History
•
Based in Leiden, Netherlands and USA
Euronext listing; 1989 - 2001 ‘Research Era’
Technology
•
Production of recombinant proteins for restoration and repair
Role of protein cascades (Complement, Clotting)
Organisation
•
2002 - 2005 ‘Turnaround & Refocus’
240
40
60 employees
Products
•
Lead product rhC1INH being filed for HAE
Clinical work on major new indications
rhLactoferrin filed for GRAS indication in USA
rhFibrinogen and rhCollagen development
Novel protein manufacturing system validated
•
•
•
Powered by Bioscience, Focused on Products
2
Strategic Evolution
Survival
• Financing
• Research
• Organisation
Focus
• rhC1 INH
• rh LF
• Cash Flow
Innovation
• Restructuring
• Compassionate Use
• Manufacturing
• Marketing
Collaboration
• Diosynth
• Paul Capital
• Novathera
• DNage
Equity
2001A
€ (1) M
2002A
€ 11 M
2004A
€ 36 M
2005A
€ 29 M
2006 - 07
€ 50 M +
Debt
€ (24) M
€ (5) M
Near Zero
Near Zero
Near Zero
Annual Loss € (54) M
€ (1) M
€ (14) M
€ (18) M
ZCB
Employees
250
40
48
60
60+
Products
1
1
4
4+
6+
Mkt Cap
€4M
€ 16 M
Powered by Bioscience, Focused on Products
€ 150 M
€ 325 M
3
Product Pipeline
Accelerate Product Flow to the Market
Product
rhC1INH
Application
Market Size
Status
HAE
> € 500 million
New Indications
> € 1 billion
Phase III
Filing in first market
In the clinic
rhFibrinogen
rhFib Sealant
Intermediate
Control bleeding
> € 1 billion
Intermediate
Device
rhLactoferrin
Nutraceutical
Anti-infective
€ 100 million
> € 1 billion
Food (GRAS)
Device
rhCollagen
Intermediate
Cosmetic / Other
> € 1 billion
Intermediate
Device
Novathera
Combos
Tissue Repair
Catheters, Stents
> € 1 billion
Under
Development
Technology
Protein Production
> € 1 billion
Licensing
Powered by Bioscience, Focused on Products
4
Protein Production
Technology
Select
protein
Generate
genetic
constructs
Develop
founder/
mini-herd
Powered by Bioscience, Focused on Products
Expand
herd
Purify
protein
from milk
Formulate
Protein
therapeutic
5
HAE - Patient Centric Approach
A congenital deficiency of functional C1 inhibitor (C1INH) characterised by recurrent
localised angioedema due to uncontrolled activation of complement and contact systems
22,000 patients, 160,000 attacks per year
relationship with
patient
organizations
share information
with regulatory
authorities
facilitating
patient care
Patient
Register
Powered by Bioscience, Focused on Products
relationships with
key opinion leaders
6
Rec. Human C1 inhibitor
Phase III for HAE
• Rapid relief
(usually 15 minutes)
• Complete resolution
(12 - 24 hours)
• No ADRs reported
• Report published
April 2005
Powered by Bioscience, Focused on Products
7
Rec. Human Lactoferrin
Filed with US FDA for GRAS
• For functional and
sport foods
• Doses of upto 2g/kg in
toxicity studies
• Safe for oral use
• Report published
Jan 2006
Powered by Bioscience, Focused on Products
8
Future Outlook 2006 – 08
Capitalize on solid financial position
•
Strong news flow from filings, partnerships and launches
for rhC1INH and rhLF
•
Partnerships for Pharming technology platforms and
product pipeline
•
Generate sustainable revenues via rhC1INH and rhLF
launches
•
Establish critical mass to build a biotechnology company
with world class R&D and commercial capabilities
Powered by Bioscience, Focused on Products
9